Effects of stenting for atherosclerotic renal artery stenosis on eGFR and predictors of clinical events in the CORAL trial

Katherine R. Tuttle, Lance D. Dworkin, William Henrich, Barbara A. Greco, Michael Steffes, Sheldon Tobe, Joseph I. Shapiro, Kenneth Jamerson, Asya Lyass, Karol Pencina, Joseph M. Massaro, Ralph B. D’Agostino, Donald E. Cutlip, Timothy P. Murphy, Christopher J. Cooper

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Background and objectives Atherosclerotic renal artery stenosis may cause kidney function loss, but effects of stenting on eGFR and clinical events associated with CKD are uncertain. Our study objectives were to determine effects of stenting on eGFR and predictors of clinical events. Design, setting, participants, & measurements: Participants (n=931) in the Cardiovascular Outcomes in Renal Artery Stenosis Trial (fromMay of 2005 to September of 2012) had >60% atherosclerotic renal artery stenosis and systolic hypertension on two or more antihypertensive drugs and/or stage >3 CKD. The intervention was stenting versus no stenting on a background of risk factor management: renin-angiotensin system inhibition, statin, antiplatelet therapy, and smoking cessation education. The effect of stenting on eGFR by the serum creatinine-cystatin C Chronic Kidney Disease Epidemiology Collaboration equation was the prespecified analysis of kidney function. Predictors of eGFR and CKD outcomes (>30% eGFR loss, ESRD, and death) and cardiovascular disease outcomes (stroke, myocardial infarction, heart failure, and death) controlling for eGFR and albuminuria were also determined. Results: eGFR was 59±24 ml/min per 1.73 m 2 (mean±SD) at baseline. Over 3 years, eGFR change, assessed by generalized estimating equations, was-1.5±7.0ml/min per 1.73m 2 per year in the stent group versus-2.3±6.3 ml/min per 1.73 m 2 per year in the medical therapy only group (P=0.18). eGFR predictors (multiple variable generalized estimating equations) were age, albuminuria, systolic BP, and diabetes (inverse associations) as well as men, total cholesterol, andHDL cholesterol (positive associations). CKDoutcomes events occurred in 19%(175 of 931), and predictors (Cox proportional hazards models) included albuminuria (positive association), systolic BP (positive association), and HDL cholesterol (inverse association). Cardiovascular disease outcomes events occurred in 22% (207 of 931), and predictors included age, albuminuria, total cholesterol, prior cardiovascular disease, and bilateral atherosclerotic renal artery stenosis (positive associations). Conclusions: Stenting did not influence eGFR in participants with atherosclerotic renal artery stenosis receiving renin-angiotensin system inhibition-based therapy. Predictors of clinical events were traditional risk factors for CKD and cardiovascular disease.

Original languageEnglish (US)
Pages (from-to)1180-1188
Number of pages9
JournalClinical Journal of the American Society of Nephrology
Volume11
Issue number7
DOIs
StatePublished - Jan 1 2016

Fingerprint

Renal Artery Obstruction
Albuminuria
Cardiovascular Diseases
Cholesterol
Renin-Angiotensin System
Kidney
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Cystatin C
Risk Management
Smoking Cessation
Group Psychotherapy
Chronic Renal Insufficiency
Proportional Hazards Models
HDL Cholesterol
Antihypertensive Agents
Chronic Kidney Failure
Stents
Creatinine
Epidemiology
Heart Failure

Keywords

  • Albuminuria
  • Blood pressure
  • Cardiovascular disease
  • Chronic kidney disease
  • Glomerular filtration rate
  • Hypertension
  • Renal Artery Obstruction
  • Renin angiotensin system
  • Stents

Cite this

Effects of stenting for atherosclerotic renal artery stenosis on eGFR and predictors of clinical events in the CORAL trial. / Tuttle, Katherine R.; Dworkin, Lance D.; Henrich, William; Greco, Barbara A.; Steffes, Michael; Tobe, Sheldon; Shapiro, Joseph I.; Jamerson, Kenneth; Lyass, Asya; Pencina, Karol; Massaro, Joseph M.; D’Agostino, Ralph B.; Cutlip, Donald E.; Murphy, Timothy P.; Cooper, Christopher J.

In: Clinical Journal of the American Society of Nephrology, Vol. 11, No. 7, 01.01.2016, p. 1180-1188.

Research output: Contribution to journalArticle

Tuttle, KR, Dworkin, LD, Henrich, W, Greco, BA, Steffes, M, Tobe, S, Shapiro, JI, Jamerson, K, Lyass, A, Pencina, K, Massaro, JM, D’Agostino, RB, Cutlip, DE, Murphy, TP & Cooper, CJ 2016, 'Effects of stenting for atherosclerotic renal artery stenosis on eGFR and predictors of clinical events in the CORAL trial', Clinical Journal of the American Society of Nephrology, vol. 11, no. 7, pp. 1180-1188. https://doi.org/10.2215/CJN.10491015
Tuttle, Katherine R. ; Dworkin, Lance D. ; Henrich, William ; Greco, Barbara A. ; Steffes, Michael ; Tobe, Sheldon ; Shapiro, Joseph I. ; Jamerson, Kenneth ; Lyass, Asya ; Pencina, Karol ; Massaro, Joseph M. ; D’Agostino, Ralph B. ; Cutlip, Donald E. ; Murphy, Timothy P. ; Cooper, Christopher J. / Effects of stenting for atherosclerotic renal artery stenosis on eGFR and predictors of clinical events in the CORAL trial. In: Clinical Journal of the American Society of Nephrology. 2016 ; Vol. 11, No. 7. pp. 1180-1188.
@article{044f7561a4064ec096abcdef6aade5a4,
title = "Effects of stenting for atherosclerotic renal artery stenosis on eGFR and predictors of clinical events in the CORAL trial",
abstract = "Background and objectives Atherosclerotic renal artery stenosis may cause kidney function loss, but effects of stenting on eGFR and clinical events associated with CKD are uncertain. Our study objectives were to determine effects of stenting on eGFR and predictors of clinical events. Design, setting, participants, & measurements: Participants (n=931) in the Cardiovascular Outcomes in Renal Artery Stenosis Trial (fromMay of 2005 to September of 2012) had >60{\%} atherosclerotic renal artery stenosis and systolic hypertension on two or more antihypertensive drugs and/or stage >3 CKD. The intervention was stenting versus no stenting on a background of risk factor management: renin-angiotensin system inhibition, statin, antiplatelet therapy, and smoking cessation education. The effect of stenting on eGFR by the serum creatinine-cystatin C Chronic Kidney Disease Epidemiology Collaboration equation was the prespecified analysis of kidney function. Predictors of eGFR and CKD outcomes (>30{\%} eGFR loss, ESRD, and death) and cardiovascular disease outcomes (stroke, myocardial infarction, heart failure, and death) controlling for eGFR and albuminuria were also determined. Results: eGFR was 59±24 ml/min per 1.73 m 2 (mean±SD) at baseline. Over 3 years, eGFR change, assessed by generalized estimating equations, was-1.5±7.0ml/min per 1.73m 2 per year in the stent group versus-2.3±6.3 ml/min per 1.73 m 2 per year in the medical therapy only group (P=0.18). eGFR predictors (multiple variable generalized estimating equations) were age, albuminuria, systolic BP, and diabetes (inverse associations) as well as men, total cholesterol, andHDL cholesterol (positive associations). CKDoutcomes events occurred in 19{\%}(175 of 931), and predictors (Cox proportional hazards models) included albuminuria (positive association), systolic BP (positive association), and HDL cholesterol (inverse association). Cardiovascular disease outcomes events occurred in 22{\%} (207 of 931), and predictors included age, albuminuria, total cholesterol, prior cardiovascular disease, and bilateral atherosclerotic renal artery stenosis (positive associations). Conclusions: Stenting did not influence eGFR in participants with atherosclerotic renal artery stenosis receiving renin-angiotensin system inhibition-based therapy. Predictors of clinical events were traditional risk factors for CKD and cardiovascular disease.",
keywords = "Albuminuria, Blood pressure, Cardiovascular disease, Chronic kidney disease, Glomerular filtration rate, Hypertension, Renal Artery Obstruction, Renin angiotensin system, Stents",
author = "Tuttle, {Katherine R.} and Dworkin, {Lance D.} and William Henrich and Greco, {Barbara A.} and Michael Steffes and Sheldon Tobe and Shapiro, {Joseph I.} and Kenneth Jamerson and Asya Lyass and Karol Pencina and Massaro, {Joseph M.} and D’Agostino, {Ralph B.} and Cutlip, {Donald E.} and Murphy, {Timothy P.} and Cooper, {Christopher J.}",
year = "2016",
month = "1",
day = "1",
doi = "10.2215/CJN.10491015",
language = "English (US)",
volume = "11",
pages = "1180--1188",
journal = "Clinical Journal of the American Society of Nephrology",
issn = "1555-9041",
publisher = "American Society of Nephrology",
number = "7",

}

TY - JOUR

T1 - Effects of stenting for atherosclerotic renal artery stenosis on eGFR and predictors of clinical events in the CORAL trial

AU - Tuttle, Katherine R.

AU - Dworkin, Lance D.

AU - Henrich, William

AU - Greco, Barbara A.

AU - Steffes, Michael

AU - Tobe, Sheldon

AU - Shapiro, Joseph I.

AU - Jamerson, Kenneth

AU - Lyass, Asya

AU - Pencina, Karol

AU - Massaro, Joseph M.

AU - D’Agostino, Ralph B.

AU - Cutlip, Donald E.

AU - Murphy, Timothy P.

AU - Cooper, Christopher J.

PY - 2016/1/1

Y1 - 2016/1/1

N2 - Background and objectives Atherosclerotic renal artery stenosis may cause kidney function loss, but effects of stenting on eGFR and clinical events associated with CKD are uncertain. Our study objectives were to determine effects of stenting on eGFR and predictors of clinical events. Design, setting, participants, & measurements: Participants (n=931) in the Cardiovascular Outcomes in Renal Artery Stenosis Trial (fromMay of 2005 to September of 2012) had >60% atherosclerotic renal artery stenosis and systolic hypertension on two or more antihypertensive drugs and/or stage >3 CKD. The intervention was stenting versus no stenting on a background of risk factor management: renin-angiotensin system inhibition, statin, antiplatelet therapy, and smoking cessation education. The effect of stenting on eGFR by the serum creatinine-cystatin C Chronic Kidney Disease Epidemiology Collaboration equation was the prespecified analysis of kidney function. Predictors of eGFR and CKD outcomes (>30% eGFR loss, ESRD, and death) and cardiovascular disease outcomes (stroke, myocardial infarction, heart failure, and death) controlling for eGFR and albuminuria were also determined. Results: eGFR was 59±24 ml/min per 1.73 m 2 (mean±SD) at baseline. Over 3 years, eGFR change, assessed by generalized estimating equations, was-1.5±7.0ml/min per 1.73m 2 per year in the stent group versus-2.3±6.3 ml/min per 1.73 m 2 per year in the medical therapy only group (P=0.18). eGFR predictors (multiple variable generalized estimating equations) were age, albuminuria, systolic BP, and diabetes (inverse associations) as well as men, total cholesterol, andHDL cholesterol (positive associations). CKDoutcomes events occurred in 19%(175 of 931), and predictors (Cox proportional hazards models) included albuminuria (positive association), systolic BP (positive association), and HDL cholesterol (inverse association). Cardiovascular disease outcomes events occurred in 22% (207 of 931), and predictors included age, albuminuria, total cholesterol, prior cardiovascular disease, and bilateral atherosclerotic renal artery stenosis (positive associations). Conclusions: Stenting did not influence eGFR in participants with atherosclerotic renal artery stenosis receiving renin-angiotensin system inhibition-based therapy. Predictors of clinical events were traditional risk factors for CKD and cardiovascular disease.

AB - Background and objectives Atherosclerotic renal artery stenosis may cause kidney function loss, but effects of stenting on eGFR and clinical events associated with CKD are uncertain. Our study objectives were to determine effects of stenting on eGFR and predictors of clinical events. Design, setting, participants, & measurements: Participants (n=931) in the Cardiovascular Outcomes in Renal Artery Stenosis Trial (fromMay of 2005 to September of 2012) had >60% atherosclerotic renal artery stenosis and systolic hypertension on two or more antihypertensive drugs and/or stage >3 CKD. The intervention was stenting versus no stenting on a background of risk factor management: renin-angiotensin system inhibition, statin, antiplatelet therapy, and smoking cessation education. The effect of stenting on eGFR by the serum creatinine-cystatin C Chronic Kidney Disease Epidemiology Collaboration equation was the prespecified analysis of kidney function. Predictors of eGFR and CKD outcomes (>30% eGFR loss, ESRD, and death) and cardiovascular disease outcomes (stroke, myocardial infarction, heart failure, and death) controlling for eGFR and albuminuria were also determined. Results: eGFR was 59±24 ml/min per 1.73 m 2 (mean±SD) at baseline. Over 3 years, eGFR change, assessed by generalized estimating equations, was-1.5±7.0ml/min per 1.73m 2 per year in the stent group versus-2.3±6.3 ml/min per 1.73 m 2 per year in the medical therapy only group (P=0.18). eGFR predictors (multiple variable generalized estimating equations) were age, albuminuria, systolic BP, and diabetes (inverse associations) as well as men, total cholesterol, andHDL cholesterol (positive associations). CKDoutcomes events occurred in 19%(175 of 931), and predictors (Cox proportional hazards models) included albuminuria (positive association), systolic BP (positive association), and HDL cholesterol (inverse association). Cardiovascular disease outcomes events occurred in 22% (207 of 931), and predictors included age, albuminuria, total cholesterol, prior cardiovascular disease, and bilateral atherosclerotic renal artery stenosis (positive associations). Conclusions: Stenting did not influence eGFR in participants with atherosclerotic renal artery stenosis receiving renin-angiotensin system inhibition-based therapy. Predictors of clinical events were traditional risk factors for CKD and cardiovascular disease.

KW - Albuminuria

KW - Blood pressure

KW - Cardiovascular disease

KW - Chronic kidney disease

KW - Glomerular filtration rate

KW - Hypertension

KW - Renal Artery Obstruction

KW - Renin angiotensin system

KW - Stents

UR - http://www.scopus.com/inward/record.url?scp=85009281201&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85009281201&partnerID=8YFLogxK

U2 - 10.2215/CJN.10491015

DO - 10.2215/CJN.10491015

M3 - Article

C2 - 27225988

AN - SCOPUS:85009281201

VL - 11

SP - 1180

EP - 1188

JO - Clinical Journal of the American Society of Nephrology

JF - Clinical Journal of the American Society of Nephrology

SN - 1555-9041

IS - 7

ER -